Profil
Cécile Chartier currently works at Cellectis SA, as Director from 2023 and NextVivo, Inc., as Chief Scientific Officer.
Dr. Chartier also formerly worked at Mereo BioPharma 5, Inc., as Senior Director-Target Validation and Iovance Biotherapeutics, Inc., as Vice President-Research from 2017 to 2021.
Dr. Chartier received her doctorate degree from Universite Louis Pasteur Strasbourg I.
Postes actifs de Cécile Chartier
| Sociétés | Poste | Début |
|---|---|---|
| CELLECTIS S.A. | Directeur/Membre du Conseil | 27/06/2023 |
NextVivo, Inc.
NextVivo, Inc. Packaged SoftwareTechnology Services Develops organoid technology platform for drug development services | Directeur Technique/Scientifique/R&D | - |
Anciens postes connus de Cécile Chartier
| Sociétés | Poste | Fin |
|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 01/01/2021 |
| ONCOMED PHARMACEUTICALS INC | Corporate Officer/Principal | - |
Formation de Cécile Chartier
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
Mereo BioPharma 5, Inc.
Mereo BioPharma 5, Inc. Pharmaceuticals: MajorHealth Technology Develops anti-cancer stem cell therapeutics | Health Technology |
Cellectis SA
Cellectis SA Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops immunotherapies | Health Technology |
Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics, Inc. BiotechnologyHealth Technology Develops biotechnological products for the treatment of cancer | Health Technology |
NextVivo, Inc.
NextVivo, Inc. Packaged SoftwareTechnology Services Develops organoid technology platform for drug development services | Technology Services |
Universite Louis Pasteur Strasbourg I
Universite Louis Pasteur Strasbourg I Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
















